Intervention

Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting1

Common conditions6

Lead sponsors shown2

Clinical trials

2 shown

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan ProcedureNCT07482943 · 2026-07-01

Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DICNCT07436663 · 2026-02-01

NOT_YET_RECRUITING

Common conditions

Breast Cancer1 Cardiovascular Diseases1 Dapagliflozin1 Fontan1 Heart Failure1 Sodium-GLucose coTransporter-2 Inhibitors1

Leading sponsors

Tanta University1 The University of Hong Kong1

Trial status mix

NOT_YET_RECRUITING1

RECRUITING1

Phase mix

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.